- Clone
- ZAQ5 (See other available formats)
- Regulatory Status
- RUO
- Other Names
- CMRF35-like molecule 9, CLM-9, CD300g, D11Ertd736e
- Isotype
- Rat IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
- publications
CD300LG, also known as nepmucin (a not expressed in Peyer's patches mucin), is a member of the CD300 antigen like family. It is a 50-95 kD glycoprotein with one IgV like domain and one mucin like domain and four isoforms are produced by alternative splicing. Nepmucin is expressed on high endothelial venules (HEV) from lymph nodes, but is absent on HEV from the Peyer's patches. CD300LG mediates lymphocyte adhesion through the intraction of its Ig domain with ICAM-1 and rolling on HEVs through the interaction of its mucin like domain with L-selectine. Also, it may play a role in the molecular transcytosis across the capillary endothelium.
Product DetailsProduct Details
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Nepmucin-Fc fusion protein
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography.
- Concentration
- 0.5 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C.
- Application
-
FC - Quality tested
EM - Reported in the literature, not verified in house - Recommended Usage
-
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
-
Additional reported applications for the relevant formats include: immunoelectron microscopy of peripheral LN HEVs1.
-
Application References
(PubMed link indicates BioLegend citation) -
- Umemoto E, et al. 2006. J. Exp. Med. 203:1603. (EM)
- Jin S, et al. 2008. FEBS Lett. 582:3018.
- Umemoto E, et al. 2011. Crit. Rev. Immunol. 31:147.
- Umemoto E, et al. 2013. PLoS One 8:e83681.
- RRID
-
AB_2562968 (BioLegend Cat. No. 147102)
Antigen Details
- Structure
- Sialomucin, member of the CD300 antigen like family, 50-95 kD. 1 IgV like domain, 1 mucin like domain. Four isoforms produced by alternative splicing.
- Distribution
-
Expressed on high endothelial venules (HEVs) from lymph nodes but absent on HEVs from Peyer's patches, some myeloid cell lines.
- Function
- Mediator of lymphocyte adhesion and rolling on HEVs, possible role in transcytosis across the capillary endothelium.
- Ligand/Receptor
- L-selectin.
- Biology Area
- Cell Adhesion, Cell Biology, Immunology
- Molecular Family
- Adhesion Molecules, CD Molecules
- Antigen References
-
1. Takatsu H, et al. 2006. Biochem. Biophys. Res. Commun. 348:183.
2. Umemoto E, et al. 2006. J. Exp. Med. 203:1603.
3. Umemoto E, et al. 2011. Crit. Rev. Immunol. 31:147. - Gene ID
- 52685 View all products for this Gene ID
- UniProt
- View information about CD300LG on UniProt.org
Related Pages & Pathways
Pages
Other Formats
View All CD300LG Reagents Request Custom ConjugationDescription | Clone | Applications |
---|---|---|
Purified anti-mouse CD300LG (Nepmucin) | ZAQ5 | FC,EM |
PE anti-mouse CD300LG (Nepmucin) | ZAQ5 | FC |
TotalSeq™-B0416 anti-mouse CD300LG (Nepmucin) | ZAQ5 | PG |
TotalSeq™-C0416 anti-mouse CD300LG (Nepmucin) | ZAQ5 | PG |
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
-
Purified anti-mouse CD300LG (Nepmucin)
Mouse CD300LG-transfected L cells were stained with purified... -
PE anti-mouse CD300LG (Nepmucin)
Mouse CD300LG-transfected L cells were stained with CD300LG ... -
TotalSeq™-B0416 anti-mouse CD300LG (Nepmucin)
-
TotalSeq™-C0416 anti-mouse CD300LG (Nepmucin)
Follow Us